Kraemer K L, Conigliaro J, Saitz R
Center for Research on Healthcare, Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania 15213, USA.
Drugs Aging. 1999 Jun;14(6):409-25. doi: 10.2165/00002512-199914060-00002.
The alcohol withdrawal syndrome is common in elderly individuals who are alcohol dependent and who decrease or stop their alcohol intake. While there have been few clinical studies to directly support or refute the hypothesis that withdrawal symptom severity, delirium and seizures increase with advancing age, several observational studies suggest that adverse functional and cognitive complications during alcohol withdrawal do occur more frequently in elderly patients. Most elderly patients with alcohol withdrawal symptoms should be considered for admission to an inpatient setting for supportive care and management. However, elderly patients with adequate social support and without significant withdrawal symptoms at presentation, comorbid illness or past history of complicated withdrawal may be suitable for outpatient management. Although over 100 drugs have been described for alcohol withdrawal treatment, there have been no studies assessing the efficacy of these drugs specifically in elderly patients. Studies in younger patients support benzodiazepines as the most efficacious therapy for reducing withdrawal symptoms and the incidence of delirium and seizure. While short-acting benzodiazepines, such as oxazepam and lorazepam, may be appropriate for elderly patients given the risk for excessive sedation from long-acting benzodiazepines, they may be less effective in preventing seizures and more prone to produce discontinuation symptoms if not tapered properly. To ensure appropriate benzodiazepine treatment, dose and frequency should be individualised with frequent monitoring, and based on validated alcohol withdrawal severity measures. Selected patients who have a history of severe or complicated withdrawal symptoms may benefit from a fixed schedule of benzodiazepine provided that medication is held for sedation. beta-Blockers, clonidine, carbamazepine and haloperidol may be used as adjunctive agents to treat symptoms not controlled by benzodiazepines. Lastly, the age of the patient should not deter clinicians from helping the patient achieve successful alcohol treatment and rehabilitation.
酒精戒断综合征在依赖酒精且减少或停止饮酒的老年人中很常见。虽然很少有临床研究直接支持或反驳戒断症状严重程度、谵妄和癫痫发作会随着年龄增长而增加这一假设,但多项观察性研究表明,酒精戒断期间不良的功能和认知并发症在老年患者中确实更频繁地发生。大多数有酒精戒断症状的老年患者应考虑住院接受支持性护理和管理。然而,有足够社会支持、就诊时无明显戒断症状、无合并症或既往无复杂戒断史的老年患者可能适合门诊治疗。虽然已有100多种药物被描述用于酒精戒断治疗,但尚无研究专门评估这些药物在老年患者中的疗效。针对年轻患者的研究支持苯二氮䓬类药物是减轻戒断症状以及谵妄和癫痫发作发生率最有效的疗法。鉴于长效苯二氮䓬类药物有过度镇静的风险,短效苯二氮䓬类药物,如奥沙西泮和劳拉西泮,可能适用于老年患者,但它们在预防癫痫发作方面可能效果较差,如果不减量适当,更容易产生停药症状。为确保苯二氮䓬类药物的适当治疗,剂量和频率应个体化,并频繁监测,且基于经过验证的酒精戒断严重程度测量方法。有严重或复杂戒断症状史的特定患者,只要为镇静而使用药物,可能会从固定剂量的苯二氮䓬类药物治疗方案中获益。β受体阻滞剂、可乐定、卡马西平和氟哌啶醇可作为辅助药物用于治疗苯二氮䓬类药物无法控制的症状。最后,患者的年龄不应阻碍临床医生帮助患者成功实现酒精治疗和康复。